Meeting
2023 ASCO Annual Meeting
Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of non-small cell lung cancer patients with brain metastases at diagnosis.
Authors
Benoît Nigen
Nantes University Hospital, Nantes, France
Benoît Nigen , Laurent Mathiot , Thomas Goronflot , Guillaume Herbreteau , Christine Sagan , Judith Raimbourg , Jaafar Bennouna , Francois Thillays , Elvire Pons-Tostivint
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9058)
DOI
10.1200/JCO.2023.41.16_suppl.9058
Abstract #
9058
Poster Bd #
46
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.
First Author: R. Brian Mitchell
Poster
2023 ASCO Annual Meeting
Discontinuation of immunotherapy over 2 years for patients with non–small cell lung cancer (NSCLC): A search for predictors.
First Author: Priscilla Cascetta
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy.
First Author: Deirdre Jill Cohen